ArticleMolecular genetics and metabolism reports2026
Prevalence and sociodemographic, clinical, and genetic characteristics of Fabry disease in north-central Chile, 2013-2023.
Article in Molecular genetics and metabolism reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fabry disease (FD) is a rare genetic disorder linked to X chromosome, causing progressive multisystem involvement. Epidemiological data on FD are limited, both in Latin America and Chile. This study aimed to estimate the prevalence of FD and describe the sociodemographic and clinical characteristics of affected individuals in a north-central region of Chile. Methods: A descriptive cross-sectional study was conducted on 69 patients with FD during the period 2013-2023. An anonymized questionnaire collected data on sociodemographic variables, enzyme replacement therapy (ERT), chronic medications, clinical manifestations, and genetic variants. Descriptive statistics and correlation tests were used. Prevalence was estimated using official population data. Results: The regional prevalence rate was 8.44 per 100,000 inhabitants (95% CI: 6.44-10.43), with a particularly high rate in the commune of Coquimbo (22.45 per 100,000 inhabitants). The majority were women (58.0%), with a mean age of 35.8 years. 94% had the classical form of FD, and 98.6% carried the c.776C > G (p.P259R) variant. ERT was initiated in 2016 for 58% of patients, and 55.1% received agalsidase alfa. Peripheral nervous system involvement was present in 71.0%, and kidney involvement in 39.1%. The older the patient, the more systems are affected. 46.4% used complementary drugs, mostly analgesics, antihypertensives and antineuropathics, whose consumption increases with age. Conclusions: The Coquimbo Region has the highest prevalence of FD in Chile. Age at treatment initiation influences system involvement and chronic medication use. The results highlight the need for additional genetic, epidemiological, and clinical studies in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.